These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16442844)

  • 21. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
    Avgeropoulou C; Andreadou I; Markantonis-Kyroudis S; Demopoulou M; Missovoulos P; Androulakis A; Kallikazaros I
    Eur J Heart Fail; 2005 Aug; 7(5):882-7. PubMed ID: 15921958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to: "Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al.".
    Damman K; Voors AA
    Cardiovasc Drugs Ther; 2007 Dec; 21(6):403-4. PubMed ID: 18030611
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
    Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.
    Büyüklü M; Kürüm AT; Tatlý E; Set T
    Arq Bras Cardiol; 2012 Jul; 99(1):659-64. PubMed ID: 22735864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of levosimendan in acute heart failure and its effect on renal function].
    Moyano AP; Hidalgo RL; Grande DB; Morales SC
    Nefrologia; 2009; 29(6):616-7. PubMed ID: 19936016
    [No Abstract]   [Full Text] [Related]  

  • 26. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 27. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.
    Parissis JT; Panou F; Farmakis D; Adamopoulos S; Filippatos G; Paraskevaidis I; Venetsanou K; Lekakis J; Kremastinos DT
    Am J Cardiol; 2005 Aug; 96(3):423-6. PubMed ID: 16054474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis].
    Xu ZD; He WX; Zhao YF; Xia SX; He B; Yang T; Cao DX; Peng SL; Li J; Cao MH
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2027-9. PubMed ID: 19861257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
    Paraskevaidis IA; Bistola V; Ikonomidis I; Parissis JT; Papadopoulos C; Filippatos G; Kremastinos DT
    Am J Cardiol; 2008 Nov; 102(9):1225-9. PubMed ID: 18940297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
    Celik T; Iyisoy A; Yuksel UC; Kardesoglu E
    Int J Cardiol; 2008 Aug; 128(1):97-9; authr reply 100-2. PubMed ID: 18501448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
    Udvary E; Papp JG; Végh A
    Br J Pharmacol; 1995 Feb; 114(3):656-61. PubMed ID: 7735692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of noninvasive hemodynamic evaluation of the acute effect of levosimendan in advanced heart failure.
    Malfatto G; Della Rosa F; Rella V; Villani A; Branzi G; Blengino S; Giglio A; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2014 Apr; 15(4):322-30. PubMed ID: 24699010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the in vivo mechanism of action of levosimendan?
    MacGowan GA
    J Card Fail; 2005 Aug; 11(6):482; author reply 482-3. PubMed ID: 16105641
    [No Abstract]   [Full Text] [Related]  

  • 36. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
    Despas F; Trouillet C; Franchitto N; Labrunee M; Galinier M; Senard JM; Pathak A
    Acute Card Care; 2010 Mar; 12(1):25-30. PubMed ID: 19929264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
    Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
    Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
    Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
    Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
    JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report].
    Biegus J; Zymliński R; Kulej K; Szachniewicz J; Banasiak W; Jankowska EA; Ponikowski P
    Kardiol Pol; 2013; 71(3):275-8. PubMed ID: 23575784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.